Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech that has been effective vigilantly but unsuccessfully to produce an one off therapy, variously named Pro 140, leronlimab, as well as Vyrologix.

In development of this particular therapy, CytoDyn has cast its net wide and far both geographically and in phrases of possible indications.

CytoDyn’s inventories of leronlimab are building up, whether they’ll ever be being used is actually an open question.

While CYDY  has been dawdling, promote opportunities for leronlimab as being a combination therapy in the curing of multi-drug-resistant HIV happen to be closing.

I’m creating my fifteenth CytoDyn (OTCQB:CYDY) guide on FintechZoom to celebrate the sale of my past several shares. The 1st CytoDyn article of mine, “CytoDyn: What To Do When It’s Too Good In order to Be True?”, set out the following prediction:

Rather I expect it to be a serial disappointer. CEO Pourhassan offered such a very promotional image in the Uptick Newswire job interview that I came away with a bad viewpoint of the company.

Irony of irony, my bad viewpoint of the company has grown steadily, though the disappointment has not been financial. 2 decades ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades at $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is this that delivers a > 6 bagger at the moment still disappoints? Therein is the story; let me explain.

CytoDyn acquired its much storied treatment (which I shall refer to as leronlimab) returned in 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) targeting the CCR5 receptor of the treatment and reduction of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical development mAb with demonstrated anti-viral activity of HIV infected subjects. Today’s transaction of $3.5 zillion transfers ownership of the expertise and connected intellectual property from Progenics to CytoDyn, as well as approximately twenty five million mg of majority drug substance…. milestone payments after commencement of a level III clinical trial ($1.5 huge number of) as well as the first brand new drug program approval ($5 million), and also royalty payments of five % of net sales upon commercialization.

Since that moment, CytoDyn’s helping nous, Nader Pourhassan [NP] has turned this inauspicious acquisition right into a springboard for CytoDyn to purchase a market cap > $3.5 billion. It has done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with many therapies and multiple indications, it has this single therapies in addition to a “broad pipeline of indications” because it places it. I call some pipelines, “pipedots.” In CytoDyn’s situation it touts its leronlimab as a potentially beneficial therapy of dozens of indications.

The opening banner of its on its site (below) shows an active organization with diverse interests albeit focused on leronlimab, multiple disease types, multiple presentations and multiple publications.

Can it all be smoke and mirrors? That is a question I have been asking myself with the really start of the interest of mine in this particular company. Judging with the multiples of thousands of various comments on listings accessible via Seeking Alpha’s CytoDyn Summary page, I’m a lot from alone in this question.

CytoDyn is a traditional battleground, or maybe some could say cult stock. Its adherents are fiercely protective of the prospects of its, quick to label any bad opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *